LOW VISCOSITY PHARMACEUTICAL COMPOSITIONS CONTAINING MYCOPHENOLIC ACID FOR THE TREATMENT OF OCULAR DISORDERS
Low viscosity pharmaceutical compositions and methods for treating ocular disorders in a subject, which include mycophenolic acid or a pharmaceutically acceptable salt thereof at a concentration of 0.05% wt/wt to 0.30% wt/wt, a glucosaminoglycan at a concentration of 0.1% to 2.5% wt/wt, and optionally a betamethasone at a concentration of 0.01% to 0.08% wt/wt.
1 . A pharmaceutical composition for topical administration to an eye, the composition comprising:
a. mycophenolic acid or a pharmaceutically acceptable salt thereof at a concentration of 0.05% to 0.3% wt/wt;
b. a glucosaminoglycan at a concentration of 0.1% to 2.5% wt/wt; and
c. a viscosity of 1 to 25 centipoise (cp).
2 . The pharmaceutical composition of claim 1 , wherein the glucosaminoglycan is chondroitin sulfate.
3 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is free of hyaluronic acid and glucosamine sulfate.
4 . The pharmaceutical composition of claim 1 , wherein the viscosity is 1 to 10 cp.
5 . The pharmaceutical composition of claim 1 , further comprising a betamethasone or a pharmaceutically acceptable salt thereof at a concentration of 0.01% to 0.08% wt/wt.
6 . A method of treating ocular pain or discomfort, the method comprising topically administering to an eye of a subject suffering from ocular pain or discomfort, a therapeutically effective amount of the composition of claim 1 .
7 . The method of claim 6 , wherein the ocular pain or discomfort is from a condition selected from the group consisting of an eye allergy, a corneal abrasion, contact lens wear, STODS, ocular surgery, and an ocular surface disease.
8 . The method of claim 7 , wherein the ocular surgery is cataract surgery or refractive surgery.
9 . The method of claim 7 , wherein the ocular surface disease is selected from the group consisting of dry eye disease, contact lens induced ocular surface dry eye disease, and preservative induced ocular surface disease.
10 . The method of claim 6 , wherein the pharmaceutical composition is administered for 7 consecutive days.
11 . The method of claim 10 , wherein the pharmaceutical composition is administered for 14 or fewer consecutive days.
12 . A post-surgical ocular treatment method, comprising topically administering to an eye of a subject that has undergone ocular surgery, the pharmaceutical composition of claim 1 .
13 . The method of claim 12 , wherein the pharmaceutical composition is administered for 7 consecutive days.
14 . The method of claim 13 , wherein the pharmaceutical composition is administered for 14 or fewer consecutive days.